CD47 信号转导通路在血管疾病中的最新进展。
Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases.
机构信息
Department of Neurology, The First Hospital of Jilin University, Changchun 130021, China.
出版信息
Biomed Res Int. 2020 Jul 15;2020:4749135. doi: 10.1155/2020/4749135. eCollection 2020.
Abstract
Cardiovascular and cerebrovascular diseases caused by atherosclerosis have a high disability rate and reduce the quality of life of the population. Therefore, understanding the mechanism of atherosclerosis and its control may interfere with the progression of atherosclerosis and thus control the occurrence of diseases closely related to atherosclerosis. TSP-1 is a factor that has been found to have an antiangiogenic effect, and CD47, as the receptor of TSP-1, can participate in the regulation of antiangiogenesis of atherosclerosis. VEGF is an important regulator of angiogenesis, and TSP-1/CD47 can cause VEGF and its downstream expression. Therefore, the TSP-1/CD47/VEGF/VEGFR2 signal may have an important influence on atherosclerosis. In addition, some inflammatory factors, such as IL-1 and NLRP3, can also affect atherosclerosis. This review will be expounded focusing on the pathogenesis and influencing factors of atherosclerosis.
摘要
由动脉粥样硬化引起的心血管和脑血管疾病具有高致残率，并降低了人群的生活质量。因此，了解动脉粥样硬化的机制及其控制可能会干扰动脉粥样硬化的进展，从而控制与动脉粥样硬化密切相关的疾病的发生。TSP-1 是一种已被发现具有抗血管生成作用的因子，而 CD47 作为 TSP-1 的受体，可以参与动脉粥样硬化的抗血管生成调节。VEGF 是血管生成的重要调节剂，TSP-1/CD47 可以引起 VEGF 及其下游表达。因此，TSP-1/CD47/VEGF/VEGFR2 信号可能对动脉粥样硬化有重要影响。此外，一些炎症因子，如 IL-1 和 NLRP3，也可以影响动脉粥样硬化。本综述将重点阐述动脉粥样硬化的发病机制和影响因素。
相似文献
1
Recent Advancements in CD47 Signal Transduction Pathways Involved in Vascular Diseases.CD47 信号转导通路在血管疾病中的最新进展。
Biomed Res Int. 2020 Jul 15;2020:4749135. doi: 10.1155/2020/4749135. eCollection 2020.
2
Is CD47 a potentially promising therapeutic target in cardiovascular diseases? - Role of CD47 in cardiovascular diseases.CD47 是否是心血管疾病中一个有前景的治疗靶点？——CD47 在心血管疾病中的作用。
Life Sci. 2020 Apr 15;247:117426. doi: 10.1016/j.lfs.2020.117426. Epub 2020 Feb 13.
3
CD47 signaling pathways controlling cellular differentiation and responses to stress.控制细胞分化和应激反应的CD47信号通路。
Crit Rev Biochem Mol Biol. 2015;50(3):212-30. doi: 10.3109/10409238.2015.1014024. Epub 2015 Feb 24.
4
Interactions between CD47 and thrombospondin reduce inflammation.CD47与血小板反应蛋白之间的相互作用可减轻炎症。
J Immunol. 2007 May 1;178(9):5930-9. doi: 10.4049/jimmunol.178.9.5930.
5
Thrombospondin-1/CD47 Interaction Regulates Th17 and Treg Differentiation in Psoriasis.血小板反应蛋白 1/CD47 相互作用调节银屑病中 Th17 和 Treg 的分化。
Front Immunol. 2019 Jun 4;10:1268. doi: 10.3389/fimmu.2019.01268. eCollection 2019.
6
Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.血小板反应蛋白 1 通过 CD47 促进皮肤 T 细胞淋巴瘤的肿瘤进展。
Leukemia. 2020 Mar;34(3):845-856. doi: 10.1038/s41375-019-0622-6. Epub 2019 Nov 11.
7
Identification of TAX2 peptide as a new unpredicted anti-cancer agent.鉴定TAX2肽作为一种新的意外抗癌剂。
Oncotarget. 2015 Jul 20;6(20):17981-8000. doi: 10.18632/oncotarget.4025.
8
Bone marrow mesenchymal stromal cells with CD47 high expression via the signal transducer and activators of transcription signaling pathway preventing myocardial fibrosis.通过信号转导和转录激活因子信号通路高表达CD47的骨髓间充质基质细胞可预防心肌纤维化。
Int J Clin Exp Pathol. 2015 Sep 1;8(9):10555-64. eCollection 2015.
9
CD47 deficiency improves neurological outcomes of traumatic brain injury in mice.CD47缺陷改善小鼠创伤性脑损伤的神经学预后。
Neurosci Lett. 2017 Mar 16;643:125-130. doi: 10.1016/j.neulet.2016.12.006. Epub 2016 Dec 5.
10
Roles of TSP1-CD47 signaling pathway in senescence of endothelial cells: cell cycle, inflammation and metabolism.TSP1-CD47信号通路在内皮细胞衰老中的作用：细胞周期、炎症与代谢。
Mol Biol Rep. 2023 May;50(5):4579-4585. doi: 10.1007/s11033-023-08357-w. Epub 2023 Mar 10.
引用本文的文献
1
Therapeutic strategies targeting CD47-SIRPα signaling pathway in gastrointestinal cancers treatment.针对CD47-SIRPα信号通路的治疗策略在胃肠道癌症治疗中的应用
J Pharm Anal. 2025 Jan;15(1):101099. doi: 10.1016/j.jpha.2024.101099. Epub 2024 Sep 12.
2
The Regulation of Exosome Generation and Function in Physiological and Pathological Processes.外泌体生成和功能的调节在生理和病理过程中。
Int J Mol Sci. 2023 Dec 23;25(1):255. doi: 10.3390/ijms25010255.
3
Opportunities and challenges of CD47-targeted therapy in cancer immunotherapy.CD47 靶向治疗在癌症免疫治疗中的机遇与挑战。
Oncol Res. 2023 Nov 15;32(1):49-60. doi: 10.32604/or.2023.042383. eCollection 2023.
4
PIAS1 impedes vascular endothelial injury and atherosclerotic plaque formation in diabetes by blocking the RUNX3/TSP-1 axis.PIAS1通过阻断RUNX3/TSP-1轴来抑制糖尿病中的血管内皮损伤和动脉粥样硬化斑块形成。
Hum Cell. 2023 Nov;36(6):1915-1927. doi: 10.1007/s13577-023-00952-0. Epub 2023 Aug 16.
5
Atherosclerosis and Inflammation: Insights from the Theory of General Pathological Processes.动脉粥样硬化与炎症：通论病理过程学说的启示。
Int J Mol Sci. 2023 Apr 26;24(9):7910. doi: 10.3390/ijms24097910.
6
Blockade of CD47 function attenuates restenosis by promoting smooth muscle cell efferocytosis and inhibiting their migration and proliferation.阻断 CD47 的功能可通过促进平滑肌细胞的吞噬作用，抑制其迁移和增殖来减轻再狭窄。
J Biol Chem. 2023 Apr;299(4):104594. doi: 10.1016/j.jbc.2023.104594. Epub 2023 Mar 8.
7
Advances in neovascularization after diabetic ischemia.糖尿病性缺血后新生血管形成的进展
World J Diabetes. 2022 Nov 15;13(11):926-939. doi: 10.4239/wjd.v13.i11.926.
8
Advances in Anti-metabolic Disease Treatments Targeting CD47.靶向CD47的抗代谢疾病治疗进展
Curr Pharm Des. 2022;28(46):3720-3728. doi: 10.2174/1381612828666221006123144.
9
Anti-atherosclerotic therapies: Milestones, challenges, and emerging innovations.抗动脉粥样硬化治疗：里程碑、挑战和新兴创新。
Mol Ther. 2022 Oct 5;30(10):3106-3117. doi: 10.1016/j.ymthe.2022.08.024. Epub 2022 Sep 5.
10
Therapy Strategy of CD47 in Diffuse Large B-Cell Lymphoma (DLBCL).CD47 在弥漫性大 B 细胞淋巴瘤（DLBCL）中的治疗策略。
Dis Markers. 2021 Sep 16;2021:4894022. doi: 10.1155/2021/4894022. eCollection 2021.
本文引用的文献
1
[Progress in the study of macrophage activation and ulcerative colitis from the Notch/NF-κB/NLRP3 signaling pathway].[Notch/NF-κB/NLRP3信号通路介导巨噬细胞活化与溃疡性结肠炎的研究进展]
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2019 Oct 28;44(10):1174-1178. doi: 10.11817/j.issn.1672-7347.2019.180693.
2
Influence of miR-199a on rats with non-small cell lung cancer via regulating the HIF-1α/VEGF signaling pathway.miR-199a 通过调控 HIF-1α/VEGF 信号通路对非小细胞肺癌大鼠的影响。
Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10363-10369. doi: 10.26355/eurrev_201912_19675.
3
Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer.阻断 CD47 可有效增强抗血管生成治疗在非小细胞肺癌中的疗效。
J Immunother Cancer. 2019 Dec 11;7(1):346. doi: 10.1186/s40425-019-0812-9.
4
Anti-inflammatory cytokines IL-35 and IL-10 block atherogenic lysophosphatidylcholine-induced, mitochondrial ROS-mediated innate immune activation, but spare innate immune memory signature in endothelial cells.抗炎细胞因子 IL-35 和 IL-10 阻断动脉粥样硬化性溶血磷脂酰胆碱诱导的、线粒体 ROS 介导的固有免疫激活，但在血管内皮细胞中保留固有免疫记忆特征。
Redox Biol. 2020 Jan;28:101373. doi: 10.1016/j.redox.2019.101373. Epub 2019 Nov 6.
5
Macrophage polarization in atherosclerosis.动脉粥样硬化中的巨噬细胞极化。
Clin Chim Acta. 2020 Feb;501:142-146. doi: 10.1016/j.cca.2019.10.034. Epub 2019 Nov 12.
6
The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications.血管内皮生长因子在低氧和免疫抑制性肿瘤微环境中的作用：治疗意义的展望。
Med Oncol. 2019 Nov 11;37(1):2. doi: 10.1007/s12032-019-1329-2.
7
Thrombospondin-1 promotes tumor progression in cutaneous T-cell lymphoma via CD47.血小板反应蛋白 1 通过 CD47 促进皮肤 T 细胞淋巴瘤的肿瘤进展。
Leukemia. 2020 Mar;34(3):845-856. doi: 10.1038/s41375-019-0622-6. Epub 2019 Nov 11.
8
CAR-T "the living drugs", immune checkpoint inhibitors, and precision medicine: a new era of cancer therapy.CAR-T“活的药物”、免疫检查点抑制剂和精准医学：癌症治疗的新时代。
J Hematol Oncol. 2019 Nov 8;12(1):113. doi: 10.1186/s13045-019-0819-1.
9
IgA-Mediated Killing of Tumor Cells by Neutrophils Is Enhanced by CD47-SIRPα Checkpoint Inhibition.CD47-SIRPα 检查点抑制增强中性粒细胞通过 IgA 介导的肿瘤细胞杀伤作用。
Cancer Immunol Res. 2020 Jan;8(1):120-130. doi: 10.1158/2326-6066.CIR-19-0144. Epub 2019 Nov 5.
10
CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.CD47 阻断增强曲妥珠单抗抗肿瘤疗效依赖于抗体依赖性细胞吞噬作用。
JCI Insight. 2019 Dec 19;4(24):131882. doi: 10.1172/jci.insight.131882.
Zotero 插件